Reference health
Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review
130/130 checkable references clean · checked 2026-07-21
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 130 checked references that resolve
resolves10.1016/j.pharmthera.2012.12.002
Endocannabinoid system and mood disorders: Priming a target for new therapies
resolves10.1016/j.euroneuro.2016.08.007
Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors
resolves10.3389/fphar.2020.595635
Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
resolves10.3390/medicines5030091
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis
resolves10.1186/s42238-021-00078-w
Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic
resolves10.1155/2022/6479953
Antidepressive‐Like Effect of <i>Aegle marmelos</i> Leaf Extract in Chronic Unpredictable Mild Stress‐Induced Depression‐Like Behaviour in Rats
resolves10.1155/2018/1691428
<i>Cannabis sativa</i> L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer
resolves10.1007/s11920-018-0969-9
Social Determinants of Mental Health: Where We Are and Where We Need to Go
resolves10.3389/fneur.2023.1087011
Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries
resolves10.1111/j.1365-2125.2012.04341.x
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
resolves10.1007/s10787-022-01020-z
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
resolves10.1016/j.ejim.2021.05.002
“Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations
resolves10.1155/2023/4139117
A Comprehensive Review of the Pharmacological Importance of Dietary Flavonoids as Hepatoprotective Agents
resolves10.2147/DMSO.S369712
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
resolves10.3389/fphar.2022.989717
Cannabidiol for neurodegenerative disorders: A comprehensive review
resolves10.3390/ijms19030833
Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
resolves10.3390/molecules24081459
Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
resolves10.1089/can.2019.0052
Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence
resolves10.14740/jocmr4090
Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials
resolves10.3390/biom11050766
Can Cannabidiol Affect the Efficacy of Chemotherapy and Epigenetic Treatments in Cancer?
resolves10.3390/molecules27154961
Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
resolves10.1098/rstb.2012.0313
Endocannabinoids in nervous system health and disease: the big picture in a nutshell
resolves10.1111/j.1432-1033.1995.tb20780.x
Expression of Central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations
resolves10.1523/jneurosci.6058-10.2011
The Endogenous Cannabinoid 2-Arachidonoylglycerol Is Intravenously Self-Administered by Squirrel Monkeys
resolves10.3389/fphar.2016.00370
A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs)
resolves10.1007/s11095-023-03469-1
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
resolves10.1111/epi.16355
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
resolves10.3390/ijms21228870
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
resolves10.1016/j.neuropharm.2018.11.035
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
resolves10.1016/j.phrs.2020.105357
Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats
resolves10.2174/1570159X17666191010094849
Epigenetic Effects Mediated by Antiepileptic Drugs and their Potential Application
resolves10.1111/ejn.12561
Cannabinoid receptor type 1 receptors on
<scp>GABA</scp>
ergic vs. glutamatergic neurons differentially gate sex‐dependent social interest in mice
resolves10.3389/fnbeh.2011.00049
The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors
resolves10.1007/s00213-015-3917-y
2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons
resolves10.1038/tp.2016.195
Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose
resolves10.1002/epi4.12699
Real‐world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study
resolves10.1111/ane.13351
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
resolves10.1016/j.yebeh.2018.07.020
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
resolves10.1111/epi.17150
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
resolves10.1001/jamaneurol.2020.4607
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
resolves10.3390/ijms22168920
Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease
resolves10.1111/j.1476-5381.2011.01426.x
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
resolves10.1089/can.2019.0068
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
resolves10.1007/s40429-020-00326-8
Therapeutic Efficacy of Cannabidiol (CBD): a Review of the Evidence From Clinical Trials and Human Laboratory Studies
resolves10.3390/ijms22094294
Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action
resolves10.3389/fphar.2017.00020
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease
resolves10.1016/j.crphar.2022.100149
Role of pro-inflammatory cytokines in Alzheimer's disease and neuroprotective effects of pegylated self-assembled nanoscaffolds
resolves10.3390/ijms23052757
Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice
resolves10.1016/0091-3057(91)90386-G
Controlled clinical trial of cannabidiol in Huntington's disease
resolves10.3390/nu14102101
Cannabidiol (CBD) Dosing: Plasma Pharmacokinetics and Effects on Accumulation in Skeletal Muscle, Liver and Adipose Tissue
resolves10.3390/ijms22041863
Cannabidiol as a Potential Treatment for Anxiety and Mood Disorders: Molecular Targets and Epigenetic Insights from Preclinical Research
resolves10.1590/1516-4446-2017-0015
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
resolves10.3389/fpsyg.2019.02466
Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders
resolves10.3389/fphar.2017.00259
Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
resolves10.1037/0033-2909.130.4.601
Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry.
resolves10.1002/phar.1780
Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents
resolves10.1177/0269881117737400
The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group
resolves10.1016/j.janxdis.2021.102429
Practical considerations for testing the effects of cannabidiol on human anxiety
resolves10.1016/j.psycom.2022.100074
Systematic literature review of human studies assessing the efficacy of cannabidiol for social anxiety
resolves10.3390/biom10050801
Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression
resolves10.1016/j.etap.2019.103202
Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model
resolves10.3390/jcm8071058
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
resolves10.1001/jamapsychiatry.2013.3947
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal
resolves10.3389/fpsyt.2022.837946
Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists
resolves10.1191/1352458504ms1048oa
Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study
resolves10.3390/biom13050846
Non-Psychoactive Cannabinoid Modulation of Nociception and Inflammation Associated with a Rat Model of Pulpitis
resolves10.1007/s00787-023-02169-w
Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review
resolves10.1186/s40798-020-00251-0
Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research
resolves10.3390/molecules25215186
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
resolves10.1007/s12640-011-9273-8
Cannabidiol-treated Rats Exhibited Higher Motor Score After Cryogenic Spinal Cord Injury
resolves10.3389/fvets.2023.1204526
Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge
resolves10.1007/s40265-021-01579-x
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
resolves10.3390/brainsci10060360
Migraine Frequency Decrease Following Prolonged Medical Cannabis Treatment: A Cross-Sectional Study
resolves10.3390/ijerph20085430
Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders
resolves10.1111/bcpt.13710
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
resolves10.1177/1756285610375328
Multiple system atrophy: current and future approaches to management
resolves10.3390/biom10111575
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
resolves10.1056/NEJMoa1611618
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
resolves10.1016/s0140-6736(18)30136-3
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
resolves10.1016/j.pediatrneurol.2017.02.009
Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome
resolves10.3389/fphar.2021.626010
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
resolves10.1016/j.addbeh.2013.03.011
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
resolves10.1586/14737175.2016.1121098
Cannabidiol as potential treatment in refractory pediatric epilepsy
resolves10.1016/j.pharmthera.2017.02.041
Cannabidiol: State of the art and new challenges for therapeutic applications
resolves10.1016/j.seizure.2023.05.003
Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome
resolves10.1176/appi.ajp.2017.17030325
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
resolves10.1016/j.msard.2022.104173
Effects of SativexⓇ on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis
resolves10.2174/157015906778019527
Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
resolves10.3390/ijms22179472
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
resolves10.3390/biomedicines11061667
Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity
resolves10.1089/can.2021.0090
Brain Penetrant, but not Peripherally Restricted, Synthetic Cannabinoid 1 Receptor Agonists Promote Morphine-Mediated Respiratory Depression
resolves10.3390/biomedicines10102492
The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases
resolves10.1111/febs.12260
Modulating the endocannabinoid system in human health and disease – successes and failures
resolves10.1097/j.pain.0000000000001386
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain
resolves10.3390/jcm8070989
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
resolves10.1089/can.2016.0034
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
resolves10.1111/j.1365-2796.2005.01553.x
Brain regulation of food intake and appetite: molecules and networks
resolves10.1097/jxx.0000000000000864
Cannabis update: Anxiety disorders and post-traumatic stress disorder
resolves10.1159/000517154
Much Ado about Dosing: The Needs and Challenges of Defining a Standardized Cannabis Unit
The 3 references without a DOI — listed, not checked
no DOI — not checkedTherapeutic effects of cannabis and cannabinoids
no DOI — not checkedInformation about mental illness and the brain
no DOI — not checkedOverview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-21 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1155/2023/8825358"><img src="https://citestamp.com/citestamped/10.1155/2023/8825358/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1155/2023/8825358)